Clinical Trial Update: Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis [Phase 3]

View source ↗

Summary

A Phase 3 intra-individual dose comparison trial of Magnevist in patients with brain metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Brain Neoplasms

Drugs mentioned

• Magnevist (gadopentetate dimeglumine)

Snippet

Sponsor: Bayer | Conditions: Brain Neoplasms | Phase 3 | Status: COMPLETED